Shengxiang Biology: Net profit in the first quarter of 2026 was 49.73 million yuan, a year-on-year decrease of 45.78%.

Shengxiang Biotech announced that its operating income in the first quarter of 2026 was 437 million yuan, a year-on-year decrease of 8.02%. Net profit was 49.7393 million yuan, a year-on-year decrease of 45.78%. During the reporting period, the company's reagent sales were still affected by factors such as centralized procurement, medical insurance cost control, and payment reform, leading to price reductions. In addition, the value-added tax rate for the company's self-produced diagnostic reagents in the in vitro diagnostics industry was increased from 3% to 13%, which had a significant impact on the company's profits.